Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17778916 | 1.00 | CYP2C9 (0.42) | CYP2C9PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL12824834 | 0.81 | CYP2C9 (0.43) | CYP2C9PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL17778511 | 0.79 | CYP2C9 (0.38) | CYP2C9PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL17777050 | 0.78 | CTRB1 (0.39) | CYP2C9CTRB1 | |
| SCHEMBL7300741 | 0.78 | CTRB1 (0.39) | CYP2C9CTRB1 | |
| SCHEMBL17776992 | 0.78 | CTRB1 (0.39) | CYP2C9CTRB1 | |
| SCHEMBL4531764 | 0.76 | OR51E2 (0.35) | — | |
| SCHEMBL19882969 | 0.76 | CYP2C9 (0.46) | CYP2C9MEN1KMT2A | |
| SCHEMBL19706645 | 0.75 | MLYCD (0.33) | MEN1KMT2A | |
| SCHEMBL25590075 | 0.75 | ASAH1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP2C9 1341/4885PRSS1 2002/4885CTSG 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.